Beijing Strong Biotechnologies,Inc.

SZSE:300406 Stock Report

Market Cap: CN¥8.3b

Beijing Strong BiotechnologiesInc Past Earnings Performance

Past criteria checks 3/6

Beijing Strong BiotechnologiesInc has been growing earnings at an average annual rate of 17.5%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 16.5% per year. Beijing Strong BiotechnologiesInc's return on equity is 13.3%, and it has net margins of 30.1%.

Key information

17.5%

Earnings growth rate

14.6%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate16.5%
Return on equity13.3%
Net Margin30.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Jul 25
Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Jul 03
Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

Jun 14
An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Mar 21
Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Mar 03
Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Feb 27
Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Revenue & Expenses Breakdown

How Beijing Strong BiotechnologiesInc makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300406 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,745526489182
30 Jun 241,747533477175
31 Mar 241,762533501170
31 Dec 231,742524499163
30 Sep 231,622491466142
30 Jun 231,615468493147
31 Mar 231,512402475142
31 Dec 221,511389475137
30 Sep 221,504364480145
30 Jun 221,504347486136
31 Mar 221,598392485133
01 Jan 221,599406463127
30 Sep 211,539335488111
30 Jun 211,391299408100
31 Mar 211,10921232188
31 Dec 2084811227279
30 Sep 2079720217777
30 Jun 2075223413772
31 Mar 2078128413769
31 Dec 1984133213670
30 Sep 1981332413166
30 Jun 1978731813265
31 Mar 1978330313263
31 Dec 1877430113161
30 Sep 1875528513361
30 Jun 1874827910484
31 Mar 1871828010969
31 Dec 1769427312154
30 Sep 1765726612937
30 Jun 176602591610
31 Mar 176582591600
31 Dec 166672721500
30 Sep 166462661420
30 Jun 165952591340
31 Mar 165902551260
31 Dec 155662451240
30 Sep 155482221260
30 Jun 155432181270
31 Mar 155242181200
31 Dec 145082111190
30 Sep 144802051070
31 Dec 13445181910

Quality Earnings: 300406 has high quality earnings.

Growing Profit Margin: 300406's current net profit margins (30.1%) are lower than last year (30.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300406's earnings have grown by 17.5% per year over the past 5 years.

Accelerating Growth: 300406's earnings growth over the past year (7.1%) is below its 5-year average (17.5% per year).

Earnings vs Industry: 300406 earnings growth over the past year (7.1%) exceeded the Biotechs industry 0.08%.


Return on Equity

High ROE: 300406's Return on Equity (13.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies